A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters.
Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.
Leombruni
Paolo
P
Department of Neurosciences, Psychiatry Section, Turin University, and Centre for Eating Disorders, Az. Ospedaliera San Giovanni Battista di Torino, Italy. paolo.leombruni@unito.it
Pierò
Andrea
A
Brustolin
Annalisa
A
Mondelli
Valeria
V
Levi
Maura
M
Campisi
Stefania
S
Marozio
Susanna
S
Abbate-Daga
Giovanni
G
Fassino
Secondo
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D052018:Bulimia Nervosa / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology*; D010555:Personality Inventory / Q000706:statistics & numerical data; D010865:Pilot Projects; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016019:Survival Analysis; D013997:Time Factors
D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline